

**Transmucosal Immediate-Release Fentanyl (TIRF)  
Risk Evaluation and Mitigation Strategy (REMS)**

*The TIRF REMS Access Program*  
a single shared system

**Current Application Holders**

**Archimedes Development Ltd.  
NDA 022569  
One Crossroads Dr., Suite 100A  
Bedminster, NJ 07921  
(908) 450-6500**

**Cephalon, Inc  
NDA 020747  
NDA 021947  
41 Moores Rd.  
Frazer, PA 19355  
(610) 344-0200**

**Meda Pharmaceuticals, Inc.  
NDA 022266  
265 Davidson Avenue #300  
Somerset, NJ 08873-4120  
(732) 564-2200**

**Prostraken, Inc.  
NDA 022510  
1430 US Highway 206  
Suite 110  
Bedminster, NJ 07921-2652  
(908) 234-1096**

**Insys Therapeutics, Inc.  
(c/o) The Weinberg Group, Inc  
NDA 202788  
1129 Twentieth Street, NW  
Suite 600  
Washington, DC 20036  
(202) 730-4101**

**Mallinckrodt Inc  
ANDA 078907  
675 McDonnell Boulevard  
Hazelwood, MO 63042  
(314) 654-3157**

**Par Pharmaceutical, Inc  
ANDA 077312**

**One Ram Ridge Road  
Spring Valley, NY 10977  
(845) 425-7100**